NICODERM CQ Drug Patent Profile

When do Nicoderm Cq patents expire, and what generic alternatives are available?

Nicoderm Cq is a drug marketed by Chattem Sanofi and is included in one NDA.

The generic ingredient in NICODERM CQ is nicotine. There are thirty drug master file entries for this compound. Twenty-nine suppliers are listed for this compound. Additional details are available on the nicotine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Nicoderm Cq

A generic version of NICODERM CQ was approved as nicotine by DIFGEN PHARMS on October 20^th, 1997.

Summary for NICODERM CQ

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	85
Clinical Trials:	37
Patent Applications:	4,660
Drug Prices:	Drug price information for NICODERM CQ
DailyMed Link:	NICODERM CQ at DailyMed

See drug prices for NICODERM CQ

See drug sales revenues for NICODERM CQ

Recent Clinical Trials for NICODERM CQ

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Rose Research Center, LLC	PHASE3
Global Action to End Smoking	PHASE3
Rose Research Center, LLC	Phase 3

See all NICODERM CQ clinical trials

Pharmacology for NICODERM CQ

Drug Class

Cholinergic Nicotinic Agonist

Paragraph IV (Patent) Challenges for NICODERM CQ

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NICODERM CQ	Transdermal System	nicotine	7 mg/24 hrs 14 mg/24 hrs 21 mg/24 hrs	020165	1	2014-05-30

US Patents and Regulatory Information for NICODERM CQ

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Chattem Sanofi	NICODERM CQ	nicotine	FILM, EXTENDED RELEASE;TRANSDERMAL	020165-006	Aug 2, 1996		OTC	Yes	No
Chattem Sanofi	NICODERM CQ	nicotine	FILM, EXTENDED RELEASE;TRANSDERMAL	020165-005	Aug 2, 1996		OTC	Yes	No
Chattem Sanofi	NICODERM CQ	nicotine	FILM, EXTENDED RELEASE;TRANSDERMAL	020165-004	Aug 2, 1996		OTC	Yes	Yes

Expired US Patents for NICODERM CQ

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Chattem Sanofi	NICODERM CQ	nicotine	FILM, EXTENDED RELEASE;TRANSDERMAL	020165-004	Aug 2, 1996	5,004,610
Chattem Sanofi	NICODERM CQ	nicotine	FILM, EXTENDED RELEASE;TRANSDERMAL	020165-004	Aug 2, 1996	9,205,059
Chattem Sanofi	NICODERM CQ	nicotine	FILM, EXTENDED RELEASE;TRANSDERMAL	020165-006	Aug 2, 1996	5,633,008
Chattem Sanofi	NICODERM CQ	nicotine	FILM, EXTENDED RELEASE;TRANSDERMAL	020165-004	Aug 2, 1996	6,165,497
Chattem Sanofi	NICODERM CQ	nicotine	FILM, EXTENDED RELEASE;TRANSDERMAL	020165-006	Aug 2, 1996	5,344,656
Chattem Sanofi	NICODERM CQ	nicotine	FILM, EXTENDED RELEASE;TRANSDERMAL	020165-004	Aug 2, 1996	5,342,623
Chattem Sanofi	NICODERM CQ	nicotine	FILM, EXTENDED RELEASE;TRANSDERMAL	020165-005	Aug 2, 1996	8,075,911

International Patents for NICODERM CQ

See the table below for patents covering NICODERM CQ around the world.

Country	Patent Number	Title	Estimated Expiration
Denmark	297690
Australia	630817
Czech Republic	302035	Prostredek pro transdermální podání nikotinu (Transparent transdermal nicotine delivery devices)
South Africa	9102753
Japan	H04500322
Hungary	0104728
South Korea	970010059

NICODERM CQ: Market Dynamics and Financial Trajectory

Last updated: April 25, 2026

What is NICODERM CQ and how does it sit in the nicotine replacement market?

NICODERM CQ is a brand of nicotine transdermal system (nicotine patch) used for smoking cessation. In most markets, nicotine replacement therapy (NRT) sits in a mature segment with:

• Low clinical differentiation across manufacturers (same active ingredient class: nicotine)
• High pricing pressure from generics and channel-specific rebates
• Steady demand tied to quit attempts rather than major new-use populations

NICODERM CQ’s commercial profile is therefore dominated by market access, pricing, and channel performance rather than step-change innovation.

How does NICODERM CQ compete: pricing, access, and switching dynamics

NRT competition is structured around three levers:

1. Therapeutic equivalence and easy substitution

   • Nicotine patch products are pharmacologically similar at the class level.
   • This accelerates switching when payers and wholesalers shift preferences to lower net-cost suppliers.

2. Formulary placement and payer rebates

   • Brand-to-generic substitution drives net price erosion for branded patch SKUs.
   • Hospital and payer formularies (when applicable) tend to prefer lowest cost per effective dosing regimen.

3. Pack economics and dosing architecture

   • Consumer behavior centers on pack size, step-down dosing schedules, and perceived “duration coverage.”
   • Shelf placement and promotional mechanics (trial offers, multi-pack bundles) materially affect net revenue even with stable unit demand.

Net effect: NICODERM CQ typically behaves like a mature OTC-adjacent branded product where volume is supported by brand recognition, while revenue per unit declines over time as competitors expand their market share.

What market signals typically drive performance for nicotine patches?

NICODERM CQ’s sales trajectory generally tracks a set of external drivers:

• Smoking prevalence and quit-rate trends in target geographies
• Regulatory actions and taxes influencing consumption patterns (including duty changes that can increase quit pressure)
• Public health campaigns that increase NRT utilization in quit attempts
• Competitive intensity from other NRT forms (gum, lozenges, inhalers) and patch generics

Because NICODERM CQ is a patch and the class is broadly substitutable, performance is most sensitive to:

• payer and retailer price competitiveness
• availability of lower-priced equivalents
• the ability to maintain shelf and e-commerce share against generics

How has the product’s patent and exclusivity position shaped financial outcomes?

NICODERM CQ is an established nicotine patch brand in the United States. The brand’s long-run revenue trajectory is structurally shaped by the reality that nicotine patch technology and active ingredient are no longer protected by meaningful brand exclusivity in most jurisdictions.

From an investment perspective, this matters because:

• patent expiry increases generic entry and accelerates net price decline
• brand value shifts from exclusivity to marketing, distribution, and pack economics

In mature NRT classes, once generics scale, branded revenue often transitions from growth to:

• share preservation (stable units)
• margin compression (lower net pricing)
• reliance on promotional spend and channel differentiation

What is the likely financial trajectory pattern for NICODERM CQ?

Given the mature and substitutable nature of nicotine patches, NICODERM CQ’s financial trajectory typically follows a pattern seen across branded NRT:

1. Initial plateau with brand-led volume stability

   • Sustained demand from consumers who seek a known brand or prefer patch convenience

2. Progressive net price erosion after generic competition scales

   • Revenue decline can occur even if unit volume is stable
   • Promotional intensity rises to defend share

3. Later-stage stabilization at lower price points

   • Brand may retain a segment based on habit, form preference, and channel relationships
   • Revenue becomes a function of continued market access, not differentiation

In short: NICODERM CQ is more likely to show declining revenue per unit over time, with total revenue tracking the combined effect of unit retention and pricing pressure.

How do channel economics typically impact reported revenue and profitability?

For nicotine patch products, the financials are strongly influenced by distribution structure:

• Retail and pharmacy channels reward the lowest net cost across comparable dosing regimens.
• E-commerce can increase transparency on price, intensifying discount competition.
• Promotional spending can be frequent near peak quitting seasons in many markets, pressuring gross-to-net margins.

A branded product with no meaningful differentiation often faces:

• rising trade spend
• lower wholesale margins
• continued marketing expense to defend share

This typically compresses EBITDA contribution even when sales units remain steady.

How should investors and R&D leaders interpret NICODERM CQ’s trajectory in a portfolio context?

NICODERM CQ should be modeled like a cash-flow stabilizer with limited growth upside rather than a growth engine.

Actionable implications:

• Pricing risk dominates: net price and gross-to-net dynamics matter more than patient growth assumptions.
• Share defense is the workstream: marketing effectiveness and channel allocations drive outcomes.
• Cost discipline matters: branded-margin durability depends on controlling trade and promotion.

For companies allocating R&D capital, NICODERM CQ does not represent a typical platform for breakthrough medical innovation because the active ingredient category is mature; competitive advantage is primarily commercial.

What should be monitored to forecast near-term performance?

Key leading indicators for nicotine patch brands include:

• Net pricing trends vs generic equivalents
• Formulary preference changes and pharmacy benefit dynamics
• Promotional intensity (bundle deals, couponing, seasonal pushes)
• Channel mix shift (retail vs e-commerce)
• Regulatory and tax actions that alter quit incentives and consumptions patterns

These are the variables most likely to move revenue faster than clinical outcomes.

---

Key Takeaways

• NICODERM CQ operates in a mature, substitutable nicotine patch segment where pricing and channel access dominate.
• Generic scaling typically drives net price erosion, which can reduce revenue even when unit demand is stable.
• The likely long-run pattern is share preservation with margin compression, producing limited growth upside.
• Forecasting should prioritize gross-to-net drivers, promotional intensity, and channel mix, not differentiation claims.

---

FAQs

1) Is NICODERM CQ a prescription product or OTC?

NICODERM CQ is used for smoking cessation as a nicotine transdermal patch product in the NRT class, with availability varying by market and label status.

2) Why do nicotine patch brands lose pricing power over time?

Nicotine patches are pharmacologically substitutable at the class level. Generic and lower-cost equivalents pressure net pricing through payer and retailer preference.

3) What most influences NICODERM CQ unit demand?

Quit attempts and consumer adoption of NRT, shaped by smoking prevalence trends and public health efforts, typically drive baseline demand.

4) What most influences NICODERM CQ revenue more than volume?

Gross-to-net economics, including rebates, discounts, and promotional intensity, typically move revenue faster than clinical differentiation.

5) Does NICODERM CQ have the same value driver as newer branded therapies?

No. In mature NRT, the primary drivers are commercial access and price competitiveness rather than long-term exclusivity from novel drug mechanisms.

---

References

[1] FDA. “Nicotine Replacement Therapy (NRT).” U.S. Food and Drug Administration. https://www.fda.gov/
[2] CDC. “Quitting Smoking: Using Nicotine Replacement Therapy.” Centers for Disease Control and Prevention. https://www.cdc.gov/
[3] NHS. “Nicotine patches.” National Health Service. https://www.nhs.uk/
[4] WHO. “WHO report on the global tobacco epidemic” (relevant sections on cessation support and NRT context). World Health Organization. https://www.who.int/